2803 (HKD) | 9803 (USD)
A multi-factor approach to capture high quality contributors to China's real economy growth
3173 (HKD) | 9173 (USD)
Capture new economic engines in consumer, technology, healthcare sectors in a multi-factor approach
3151 (HKD) | 83151 (RMB) | 9151 (USD)
Leading technological innovation-based companies listed on the SSE STAR Board
3181 (HKD) | 9181 (USD)
An efficient solution to capture digital transformation, robotics & automation, and healthcare & life science innovations in Asia
2810 (HKD) | 9810 (USD)
A low cost building block capturing the leading powerhouses in Malaysia, Thailand, Indonesia, the Philippines and Vietnam
2804 (HKD) | 9804 (USD)
Efficient, in-time-zone access to capture exponential growth opportunities from Vietnam equities in a single trade
2817 (HKD) | 82817 (RMB) | 9817 (USD)
9177 (USD)
Unique, transparent and low-cost tool to conveniently access Long Duration China Government Bonds
3001 (HKD) | 83001 (RMB) | 9001 (USD)
First SFC authorized high yield bond ETF to capture attractive USD yield from a diversified basket of secured and senior USD China property bonds
3077 (HKD) | 9077 (USD)
9078 (USD)
Cash management tool with daily liquidity, minimal duration exposure, US treasury credit quality and little counterparty risk
3411 (HKD) | 9411 (USD)
Cash management tool with daily liquidity, minimal duration exposure, US treasury credit quality and little counterparty risk
3453 (HKD)
9159 (USD)
An efficient solution to capture digital transformation, robotics & automation, and healthcare & life science innovations in Asia
3478 (HKD) | 9478 (USD)
Asia's first ETF offering convenient access to Saudi Arabia government sukuk market through a one-ticker trade
featured insights & webinar
China's biopharmaceutical industry is undergoing a landmark transformation, emerging from a period of profound recalibration to establish itself as a global powerhouse. Propelled by its talent, patient access, cost-efficient infrastructure, and catalysed by comprehensive government policies aimed at supporting the innovative drug value chain, the sector is experiencing a broad-based resurgence, with results beginning to show in earnings and valuations in the first half of the year. The journey, however, is just beginning, fueled by the impending global patent cliff and its strong value proposition: delivering high-quality, innovative medicines at an accelerated pace. This capability ensures China's biopharma sector an indispensable player in the global market, even in the face of possible geopolitical headwinds. In this article, we discuss about the leading innovators in the homegrown biotech landscape—companies well-represented in our Premia China New Economy ETF (3173/9173 HK) and Premia China STAR50 ETF (3151/9151/83151 HK), which have outperformed multiple benchmarks year-to-date and will continue to drive alpha returns for global investors, propelled by a revaluation trend driven by domestic policy tailwinds, strong external partnerships and a rising market value.
Oct 03, 2025
Vietnam stands out as Asia’s best-performing equity market in 2025, fueled by earnings recovery, policy support, and surging public investment. More importantly, Resolution 68 marks the country’s boldest reform agenda since Doi Moi—streamlining bureaucracy, empowering the private sector, and deepening capital markets—creating structural upside beyond cyclical drivers. With infrastructure projects worth over 10% of GDP, robust FDI inflows, and the potential MSCI/FTSE upgrade unlocking sizable foreign flows, Vietnam offers a rare blend of near-term catalysts and long-term growth. In this article, our Partner & Co-CIO David Lai discusses how Premia Vietnam ETF offers investors a diversified, transparent, and cost-effective vehicle that has consistently outperformed active peers—positioning portfolios to capture one of the most compelling reform-driven growth stories in emerging Asia.
Sep 12, 2025
China’s A-share market is turning the corner, as investors looking past weak data and piling back into growth. Signs of rotation by domestic investors from bank deposits and safe haven assets to equity market increasingly validate investor confidence is back. Policy momentum, attractive valuations, and light foreign positioning are fueling a durable rally, echoing the 2016 supply-side reform. Leadership is shifting decisively to innovation-driven sectors — from biotech and healthcare to solar, AI, and robotics — where structural growth and global relevance are accelerating, and are expected to be important focus in China’s upcoming 15th Five Year Plan. In this article, our Partner & Co-CIO David Lai and Portfolio Manager Alex Chu discuss why, with sentiment improving and risk appetite returning, the best way to play China’s new growth cycle is through high-conviction exposure via Premia’s STAR50 ETF and CSI Caixin New Economy ETF.
Aug 26, 2025
China's STAR Market appears poised for a major growth surge, fueled by a wave of innovative robotics companies set to launch their initial public offerings. Leading industry players, including Unitree, Zhiyuan Robot, Jaka Robotics, Fine Motion Tech, and Sichuan Tianlian Robot, are all in the IPO pipeline. In this article, we will introduce these firms that are at the forefront of technological innovation in humanoid and industrial robotics, whose momentum is expected to accelerate, driven by ongoing industry innovation and the favorable policy tailwinds of China's upcoming 15th Five-Year Plan.
Aug 25, 2025
Even for the prepared and informed, at the recent World Artificial Intelligence Conference (WAIC 2025), China has still taken the world by surprise with the debutante of its fleet of over 150 AI-powered humanoid robots. Indeed 2025 marks the beginning of commercialization and production of these futuristic robots, now made reality. While humanoid robots have captured the imagination of the popular media, there has been a more important revolution in the broader robotics industry, where China has emerged, as the global powerhouse, just as it did in renewable energy and electric vehicles. In this article, we discuss how humanoid industrial robots have quickly been integrated in China’s production lines, filling the productivity void from the country’s aging population, while further driving down the manufacturing production costs with high degree of automation with these embodied AI applications.
Aug 06, 2025
Equities around the world rebounded from early-April “Liberation Day” lows, as markets increasingly reckoned the White House’s tariff bark may be worse than its bite, leading stocks in China—one of America’s biggest trading partners, and an economy viewed to be in the crosshairs of Trump 2.0 trade policy—to rise in Q2. In this article, Dr. Phillip Wool, Global Head of Research of Rayliant Global Advisors, discusses the presently muted impact of tariffs on China’s exports and explain what might be needed to ensure a sustained A-share rally.
Jul 31, 2025
Chart Of the Week


David Lai , CFA
CFA
Vietnam’s long-awaited upgrade to Emerging Market (EM) status by FTSE Russell marks a pivotal milestone in the evolution of its capital markets. Yet, contrary to the notion that “the good news is already priced in,” history suggests it is far from too late to gain exposure. Past FTSE EM upgrades show that markets tend to continue outperforming well after the announcement—with Pakistan, Kuwait, China A-shares, Romania, and Saudi Arabia outperforming the MSCI EM Index by 66.22%, 28.42%, 20.55%, 15.91%, and 11.11%, respectively, in USD terms during the period from announcement to 12 months post-inclusion. Only Iceland proved an exception at -16.94%. These precedents highlight how structural inflows, valuation re-ratings, and improved investor access typically sustain positive momentum well beyond the initial upgrade news. In Vietnam’s case, the reclassification is just one milestone in a broader reform journey. Ongoing initiatives — including the rollout of a Central Counterparty Clearing (CCP) system, stronger corporate governance, digitalization of market infrastructure, and enhanced foreign access — signal a deepening commitment to transparency, efficiency, and sustainability. As Prime Minister Pham Minh Chinh has reiterated, Vietnam aims to build a market that meets global standards and supports long-term economic growth through efficient capital mobilization. With key reforms still progressing and passive EM fund inflows yet to commence, Vietnam’s re-rating cycle is likely in its early stages. Investors seeking to capture this structural opportunity may consider the Premia Vietnam ETF, which targets mid- to large-cap companies poised to benefit most from Vietnam’s EM inclusion and the ensuing wave of institutional participation.
Oct 14, 2025










